

# Clotilde Mannoury La Cour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11397178/publications.pdf>

Version: 2024-02-01

36  
papers

1,917  
citations

331670

21  
h-index

361022

35  
g-index

37  
all docs

37  
docs citations

37  
times ranked

2492  
citing authors

#	ARTICLE	IF	CITATIONS
1	Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 454-464.	8.7	272
2	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. <i>Neuropharmacology</i> , 2006, 50, 941-952.	4.1	191
3	5-HT <sub>6</sub> receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. <i>EMBO Molecular Medicine</i> , 2012, 4, 1043-1056.	6.9	152
4	Regional Differences in the Coupling of 5-Hydroxytryptamine-1A Receptors to G Proteins in the Rat Brain. <i>Molecular Pharmacology</i> , 2006, 70, 1013-1021.	2.3	123
5	S32006, a novel 5-HT <sub>2C</sub> receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. <i>Psychopharmacology</i> , 2008, 199, 549-568.	3.1	109
6	Inverse Agonist and Neutral Antagonist Actions of Antidepressants at Recombinant and Native 5-Hydroxytryptamine <sub>2C</sub> Receptors: Differential Modulation of Cell Surface Expression and Signal Transduction. <i>Molecular Pharmacology</i> , 2008, 73, 748-757.	2.3	101
7	Functional Consequences of 5-HT Transporter Gene Disruption on 5-HT <sub>1A</sub> Receptor-Mediated Regulation of Dorsal Raphe and Hippocampal Cell Activity. <i>Journal of Neuroscience</i> , 2001, 21, 2178-2185.	3.6	96
8	Cdk5 induces constitutive activation of 5-HT <sub>6</sub> receptors to promote neurite growth. <i>Nature Chemical Biology</i> , 2014, 10, 590-597.	8.0	95
9	Convergence of Melatonin and Serotonin (5-HT) Signaling at MT <sub>2</sub> /5-HT <sub>2C</sub> Receptor Heteromers. <i>Journal of Biological Chemistry</i> , 2015, 290, 11537-11546.	3.4	90
10	Signaling Pathways Leading to Phosphorylation of Akt and GSK-3 $\beta$ by Activation of Cloned Human and Rat Cerebral D <sub>2</sub> and D <sub>3</sub> Receptors. <i>Molecular Pharmacology</i> , 2011, 79, 91-105. S33138	2.3	69
11	A Preferential Dopamine D <sub>3</sub> versus D <sub>2</sub> Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 587-599.	2.5	61
12	Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser280 by Hallucinogenic versus Nonhallucinogenic Agonists. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1273-1285.	3.8	58
13	The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D <sub>3</sub> and D <sub>2</sub> Receptors. <i>Molecular Pharmacology</i> , 2010, 78, 925-934.	2.3	57
14	The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT <sub>2C</sub> receptors. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 768-783.	2.1	42
15	Functional Homomers and Heteromers of Dopamine D <sub>2L</sub> and D <sub>3</sub> Receptors Co-exist at the Cell Surface. <i>Journal of Biological Chemistry</i> , 2012, 287, 8864-8878.	3.4	41
16	Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT <sub>6</sub> receptors: A comparative study of coupling to G $\alpha$ s. <i>European Journal of Pharmacology</i> , 2008, 588, 170-177.	3.5	36
17	GABAB receptors in 5-HT transporter- and 5-HT <sub>1A</sub> receptor-knock-out mice: further evidence of a transduction pathway shared with 5-HT <sub>1A</sub> receptors. <i>Journal of Neurochemistry</i> , 2004, 89, 886-896.	3.9	33
18	Transient and rapid activation of Akt/GSK-3 $\beta$ and mTORC1 signaling by D <sub>3</sub> dopamine receptor stimulation in dorsal striatum and nucleus accumbens. <i>Journal of Neurochemistry</i> , 2013, 125, 532-544.	3.9	31

#	ARTICLE	IF	CITATIONS
19	Influence of positive allosteric modulators on GABA <sub>B</sub> receptor coupling in rat brain: a scintillation proximity assay characterisation of G protein subtypes. <i>Journal of Neurochemistry</i> , 2008, 105, 308-323.	3.9	28
20	S32504, a Novel Naphthoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 903-920.	2.5	27
21	Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: A comparison to other agents. <i>European Neuropsychopharmacology</i> , 2008, 18, 729-750.	0.7	23
22	Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. <i>Neuropharmacology</i> , 2019, 144, 244-255.	4.1	22
23	Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs. <i>Neuropharmacology</i> , 2020, 177, 108099.	4.1	22
24	Isoform-Specific Biased Agonism of Histamine H <sub>3</sub> Receptor Agonists. <i>Molecular Pharmacology</i> , 2017, 91, 87-99.	2.3	21
25	Inhibitory and facilitory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: A comparison to human $\alpha$ 1- and $\alpha$ 2-adrenoceptor subtypes. <i>European Journal of Pharmacology</i> , 2010, 634, 1-9.	3.5	20
26	S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: A comparison to aprepitant (MK869) and paroxetine. <i>European Neuropsychopharmacology</i> , 2010, 20, 599-621.	0.7	16
27	Design, Synthesis, and Optimization of Balanced Dual NK <sub>1</sub> /NK <sub>3</sub> Receptor Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 550-555.	2.8	15
28	S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/ $\alpha$ 2-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 750-764.	2.5	14
29	Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6 receptor ligands with significant selectivity for D3 over D2 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 38-52.	3.0	10
30	Impaired working memory, cognitive flexibility and reward processing in mice genetically lacking Gpr88: Evidence for a key role for Gpr88 in multiple cortico-striatal-thalamic circuits. <i>Genes, Brain and Behavior</i> , 2021, 20, e12710.	2.2	9
31	Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2133-2138.	2.2	7
32	Design and synthesis of potential dual NK1/NK3 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 510-514.	2.2	7
33	Dysbindin-1 modifies signaling and cellular localization of recombinant, human D <sub>3</sub> and D <sub>2</sub> receptors. <i>Journal of Neurochemistry</i> , 2016, 136, 1037-1051.	3.9	7
34	Knock-Down of GPR88 in the Dorsal Striatum Alters the Response of Medium Spiny Neurons to the Loss of Dopamine Input and L-3-4-Dihydroxyphenylalanine. <i>Frontiers in Pharmacology</i> , 2019, 10, 1233.	3.5	7
35	Distinctive binding properties of the negative allosteric modulator, [ <sup>3</sup> H]SB269,652, at recombinant dopamine D <sub>3</sub> receptors. <i>European Journal of Pharmacology</i> , 2018, 819, 181-189.	3.5	5
36	Interaction of the preferential D3 agonist (+)PHNO with dopamine D3-D2 receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imaging. <i>European Journal of Pharmacology</i> , 2022, 925, 175016.	3.5	0